cas12175-sup-0001-DataS1-FigS1-S11.docxWord document1640K

Data S1. Materials and methods.

Fig. S1. The absence of the known driver mutations.

Fig. S2. Suppression of RET mRNA in siRET-treated cells.

Fig. S3. RET-dependent transcriptome profile in LC-2/ad cells.

Fig. S4. Dose-dependent effect of vandetanib in PC-9 cells.

Fig. S5. WST-8 assay with various kinase inhibitors.

Fig. S6. Effect of sunitinib and sorafenib on G1 phase population of LC-2/ad cells.

Fig. S7. Effect of sunitinib and sorafenib on apoptosis of LC-2/ad cells.

Fig. S8. Dose-dependent effect of AZD6244 and BEZ235 in LC-2/ad cells.

Fig. S9. WST-8 assay of LC-2/ad cells treated with AZD6244 and BEZ235.

Fig. S10. Body weight of the vandetanib-, sunitinib-, sorafenib- and vehicle-treated mice.

Fig. S11. Effect of sunitinib and sorafenib in vivo.

cas12175-sup-0002-TableS1.docxWord document21KTable S1. Polymerase chain reaction primers.
cas12175-sup-0003-TableS2.xlsapplication/msexcel292KTable S2. Summary of the microarray data.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.